Who Paid My Doc
Encequidar
Drug Metastatic Breast Cancer
General payments
$242,380
Research payments
$0
Through program year 2020, $242,380 in general payments and $0 in research payments were reported against Encequidar (Metastatic Breast Cancer).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | General | $209,820 | 298 |
| 2019 | General | $32,560 | 102 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2020.
Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.
The top 5 of 38 states; each share is of general payments naming this product in 2020 where a state was reported.
Records
400 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.